Video game-based therapy helps stroke patients
After a stroke, patients may lose feeling in an arm or experience weakness and reduced movement that limits their ability to complete basic daily activities. Traditional rehabilitation therapy is very intensive, time-consuming and can be both expensive and inconvenient, especially for rural patients travelling long distances to in-person therapy appointments. That’s why a team of […]
Check Troponin in RCC Patients Before Checkpoint-VEGFR Inhibitor Combo
Advanced renal cell carcinoma (RCC) patients with high serum levels of troponin T had a greater risk of serious cardiac events when treated with an immune checkpoint inhibitor and VEGFR inhibitor combination, data from the phase III JAVELIN Renal 101 trial indicated. For patients assigned to the avelumab (Bavencio) plus axitinib (Inlyta) arm, 17.1% of […]
Deep Learning Identifies PPMS Patients Who May Respond to Treatment
Deep learning identified subgroups of patients with primary progressive multiple sclerosis (PPMS) who may respond to disease-modifying therapy, researchers said. A trained model separated responders and non-responders across a range of predicted effect sizes, reported Jean-Pierre Falet, MD, of McGill University in Montreal, Canada, at the ACTRIMS Forum 2022, the annual meeting of the Americas […]
Dupilumab May Help in Tough-to-Treat Chronic Spontaneous Urticaria
PHOENIX — Patients who received add-on dupilumab (Dupixent) treatment for chronic spontaneous urticaria (CSU) had reduced symptoms and experienced less itchiness, a phase III trial found. In the 6-month study, participants (adults, adolescents, and children) treated with dupilumab on top of their usual H1-antihistamine (H1-AH) experienced a 4.2-point greater mean reduction in their Itch Severity […]
Black, Latinx Adults With Asthma Benefit from Inhaled Glucocorticoid Add-On
Black and Latinx patients who used an inhaled glucocorticoid as needed along with usual care had improved asthma outcomes, according to results from the PREPARE trial. In the study of patients with moderate-to-severe asthma, and compared to a control group that continued usual care only, the intervention group experienced a 15% decrease in risk of […]
Enzalutamide Rechallenge Yields Small PFS Boost in Metastatic Prostate Cancer
In patients with metastatic castration-resistant prostate cancer (CRPC) who have progressed on enzalutamide (Xtandi), those who continued the treatment in combination with docetaxel and prednisolone saw improved progression-free survival (PFS), the phase IIIb PRESIDE study found. Median PFS was 9.53 months with the the enzalutamide-based combination compared with 8.28 months in those treated with placebo […]
Darolutamide Improves OS in Metastatic Prostate Cancer
Darolutamide (Nubeqa) combined with standard treatment significantly improved survival in patients with metastatic hormone-sensitive prostate cancer (mHSPC), the phase III ARASENS trial found. At data cutoff, patients who received darolutamide plus androgen deprivation therapy (ADT) and docetaxel had a 32.5% lower risk of death compared with the group who received placebo plus the standard (HR […]
Active Cellular Immunotherapy Disappoints in Metastatic Prostate Cancer
An autologous dendritic cell-based immunotherapy (DCVAC/PCa) added to chemotherapy did not improve survival in patients with metastatic castration-resistant prostate cancer (mCRPC), a phase III trial found. Among over 1,100 men with mCRPC, median overall survival (OS) was 23.9 months in those who received DCVAC/PCa plus docetaxel-prednisone compared with 24.3 months for those who received placebo […]
Another PARP Inhibitor Active in BRCA-Mutant Prostate Cancer
A third of patients with previously treated BRCA-mutant metastatic castration-resistant prostate cancer (mCRPC) responded to the PARP inhibitor niraparib (Zejula), a prospective phase II study showed. The results showed that 26 of 76 patients with measurable disease had objective responses, 35 of whom had at least a 30% decrease in tumor size. An exploratory analysis […]
Pre-Op Atezolizumab Promising in Muscle-Invasive Bladder Cancer
The use of a checkpoint inhibitor combined with chemotherapy in the neoadjuvant setting appeared to be effective for patients with muscle-invasive bladder cancer (MIBC), according to results from a phase II trial. Among 39 patients, the addition of the PD-L1 inhibitor atezolizumab (Tecentriq) to gemcitabine and cisplatin resulted in a non-muscle-invasive downstaging rate of 69% […]